Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track ARTV with free AI briefings, catalyst countdowns, and dilution alerts.

ARTV — Artiva Biotherapeutics, Inc.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$301.5M Cash on Hand

43.8mo Cash Runway

5.6% Short Interest

🧪 Upcoming Trial Catalysts

2027-07-01 · Phase 1 — Recruiting — Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab
2027-08-01 · Phase 1 — Active Trial — AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class
2027-08-01 · Phase 1 — Recruiting — Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With
2028-01-01 · Phase 2 — Recruiting — AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Co

📊 Drug Pipeline

Drug	Indication	Phase	Status
AB-101	Relapsed or Refractory Hodgkin Lymphoma	PHASE2	TERMINATED
AFM13	Relapsed or Refractory Hodgkin Lymphoma	PHASE2	TERMINATED
Allogeneic NK Cells	Refractory Rheumatoid Arthritis (RA)	PHASE2	RECRUITING
Cyclophosphamide	Relapsed or Refractory Hodgkin Lymphoma	PHASE2	TERMINATED
Fludarabine	Relapsed or Refractory Hodgkin Lymphoma	PHASE2	TERMINATED
Interleukin-2	Relapsed or Refractory Hodgkin Lymphoma	PHASE2	TERMINATED
AB-201	Breast Cancer	PHASE1	WITHDRAWN
Bendamustine	Non Hodgkin Lymphoma	PHASE1	COMPLETED
GCC2005	Lymphoma, T-Cell	PHASE1	RECRUITING
Obinutuzumab	Lupus Nephritis - WHO Class III	PHASE1	ACTIVE_NOT_RECRUITING

💰 Cash Runway & Dilution Risk

ARTV holds $301.5M in cash and burns about $20.7M/quarter from operations, giving an estimated runway of 43.8 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ARTV free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-07-31	RA CAPITAL MANAGEMENT, L.P.	Purchase	$172.9M
2026-07-31	RA CAPITAL MANAGEMENT, L.P.	Purchase	$172.1M
2026-07-28	RA CAPITAL MANAGEMENT, L.P.	Purchase	$172.7M
2026-07-23	RA CAPITAL MANAGEMENT, L.P.	Purchase	$150.3M
2026-07-23	RA CAPITAL MANAGEMENT, L.P.	Purchase	$163.3M

Get the full ARTV picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ARTV and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z